Skip to content
Medicines & Healthcare products Regulatory Agency
The National Institute for Biological Standards and Control

Confidence in biological medicines

  • Stay connected
  • Shopping Basket
  • Pay Now
  • Login / Register
  • Home
  • Products
  • Standardisation
  • Control testing
  • Science and research
  • Expert services
  • About us
  • Register
  • Login
  • Advanced therapies
  • Virology
  • Bacteriology
  • Biotherapeutics
  • Analytical sciences
  • Infectious Disease Diagnostics
  • A to Z listing
  • Publications
  • Home  /  
  • Science and research  /  
  • Virology  /  
  • Influenza Resource Centre  /  
  • Full reagent update

Reagent update

Current availability from NIBSC of candidate influenza vaccine viruses, SRD reagents and neuraminidase reagents for use in the 2022 Southern hemisphere season and 2021-22 Northern hemisphere season (See below for pricing information)

More information can be found in the Influenza Resource Centre pages. 

Update 141 24 September 2021

Candidate influenza viruses for use in the Southern hemisphere 20222

Candidate influenza vaccine viruses

NIBSC code

H1N1
A/Victoria/2570/2019 20/216
IVR-215 reassortant derived from A/Victoria/2570/2019 20/212 & 21/252
IVR-216 reassortant derived from A/Victoria/3/2020 20/214
IVR-217 reassortant derived from A/Victoria/1/2020 20/220
X-349 reassortant derived from A/Indiana/02/2020 20/236
X-349A reassortant derived from A/Indiana/02/2020 20/238

H3N2
A/Darwin/9/2021 21/214
NIB-126 reassortant derived from A/Darwin/9/2021 21/228
IVR-228 21/246
A/Darwin/6/2021 21/212
NIB-127 reassortant derived from A/Darwin/6/2021 21/226
IVR-227 reassortant derived from A/Darwin/6/2021 21/204

B (Victoria lineage)
B/Austria/1359417/2021 In progress
BVR-26 reassortant derived from B/Austria/1359417/2021 In progress
B/Michigan/01/2021 21/244
B/Singapore/WUH4618/2021 In progress

B (Yamagata lineage)
B/Phuket/3073/2013 wild type virus 21/132
B/Brisbane/9/2014 wild type virus 14/204 (please contact for availability) 
B/Utah/9/2014 wild type virus 14/320
NYMC BX-57 reassortant derived from B/Hong Kong/3417/2014 20/134
NYMC BX-59A reassortant derived from B/California/12/2015 15/274
NYMC BX-59B reassortant derived from B/California/12/2015 15/294
NYMC BX-63 reassortant derived from B/Arizona/10/2015 17/124
NYMC BX-63A reassortant derived from B/Arizona/10/2015 17/126

2https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2022-southern-hemisphere-influenza-season

SRD reagents for use in the Southern hemisphere 20222

Reagents for influenza vaccine standardisation

NIBSC code
H1N1
A/Victoria/2570/2019 (IVR-215) antigen 20/232
A/Victoria/2570/2019 - like antiserum 20/234

B (Yamagata lineage)
B/Phuket/3073/2013 antigen 21/136
B/Utah/9/2014 (cell derived) antigen 15/100
B/Singapore/INFTT-16-0610/2016 (cell derived) antigen 19/308
B/Phuket/3073/2013 - like antiserum 19/322

2https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2022-southern-hemisphere-influenza-season

Neuraminidase reagents

NIBSC code

N1
NA antiserum prepared from A/California/7/2009 10/218
NA antiserum prepared from A/New Caledonia/20/99 04/230 (please contact for availability)

N2
NA antiserum prepared from A/Victoria/361/2011 14/144
NA antiserum prepared from A/South Australia/34/2019 19/320

B
NA antiserum prepared from B/Jiangsu/10/2003 04/228 (please contact for availability)
NA antiserum prepared from B/Malaysia/2506/2004 05/252
NA antiserum prepared for B/Florida/4/2006 09/316 (please contact for availability)
NA antiserum prepared from B/Phuket/3073/2013 In progress

Candidate influenza viruses for use in the Northern hemisphere 2021-221

Candidate influenza vaccine viruses

NIBSC code

H1N1

  
A/Victoria/2570/2019 20/216
IVR-215 reassortant derived from A/Victoria/2570/2019 20/212 &21/252
IVR-216 reassortant derived from A/Victoria/3/2020 20/214
IVR-217 reassortant derived from A/Victoria/1/2020 20/220
X-349 reassortant derived from A/Indiana/02/2020 20/236
X-349A reassortant derived from A/Indiana/02/2020 20/238

H3N2

  
A/Cambodia/E0826360/2020 20/310
IVR-224 reassortant derived from A/Cambodia/E0826360/2020 21/196
X-361A reassortant derived from A/Cambodia/E0826360/2020 21/190
A/Tasmania/503/2020 21/186
IVR-221 reassortant derived from A/Tasmania/503/2020 20/318
X-355B reassortant derived from A/Tasmania/503/2020 21/164

B (Victoria lineage)
B/Washington/02/2019 Wild-type virus 20/242
BVR-11 reassortant derived from B/Victoria/705/2018 19/172
B/Victoria/705/2018 Wild-type virus 19/176
B/Brisbane/35/2018 19/194
BX-85C reassortant derived from B/Washington/02/2019 19/256
CNIC-1906 derived from B/Sichuan-Gaoxin/531/2018 19/258
NYMC BX-87C reassortant derived from B/Hong Kong/574/2019 20/164
B/Hong Kong/574/2019 Wild-type virus 21/124

B (Yamagata lineage)

  
B/Phuket/3073/2013 wild type virus 21/132
B/Brisbane/9/2014 wild type virus 14/204 (please contact for availability)
B/Utah/9/2014 wild type virus 14/320
NYMC BX-57 reassortant derived from B/Hong Kong/3417/2014 20/134
NYMC BX-59A reassortant derived from B/California/12/2015 15/274
NYMC BX-59B reassortant derived from B/California/12/2015 15/294
NYMC BX-63 reassortant derived from B/Arizona/10/2015 17/124
NYMC BX-63A reassortant derived from B/Arizona/10/2015 17/126

1https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2021-2022-northern-hemisphere-influenza-season

SRD reagents for use in the Northern hemisphere 2021-221

(For H1N1 subtype and B Yamagata lineage reagents please see tables for Southern hemisphere 2022 above)


Reagents for influenza vaccine standardisation

NIBSC code
H3N2
A/Cambodia/E0826360/2020 (IVR-224) antigen 21/100
A/Tasmania/503/2020 (IVR-221) antigen 21/116
A/Cambodia/E0826360/2020 - like antiserum 21/118
B (Victoria lineage)
B/Washington/02/2019 antigen 19/238
B/Victoria/705/2018 (BVR-11) antigen 19/208
B/Darwin/7/2019 (cell derived) antigen 19/210
B/Washington/02/2019 - like antiserum 19/218
19/318

1https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2021-2022-northern-hemisphere-influenza-season

Pricing information

Viruses are free of charge (normally a maximum of two vials per recipient), but customers are expected to pay shipping and packing costs. Reagents for Single Radial Diffusion assay are subject to the NIBSC handling charge of £107 per vial, plus shipping and packing costs. Approved National Control Laboratories for human health are exempt from the handling fee.

Calibration of Reagents for Influenza vaccine standardisation

Reference antigens and antiserum reagents for the standardization of vaccines are produced by the following WHO laboratories:

Essential Regulatory Laboratories (ERL)

National Institute for Biological Standards and Control (NIBSC), UK

Center for Biologics Evaluation and Research (CBER), USA

National Institute for Infectious Disease (NIID), Japan

Therapeutic Goods Administration (TGA), Australia

Key staff

Othmar Engelhardt, Principal Scientist
Jason Long, Principal Scientist
Francesco Gubinelli, Senior Scientist
Basma Bahsoun, Scientist
Victoria Bailey, Scientist
Sitara Dubey, Scientist
Elli Elenoglou, Scientist
Kajetan Rakowski, Scientist

  • Careers
  • Terms and conditions
  • Accessibility
  • Privacy notice
  • Cookies
  • Sitemap